Plasminogen is present in the serum at a concentration of about 2 M and is concentrated at the endothelial cell surface by virtue of its binding to cell-surface receptors such as annexin II tetramer (reviewed in Ref. 1) . Plasminogen is converted to the active two-chain form, plasmin, by the cleavage of Arg 561 -Val 562 bond by tissue plasminogen activator or urokinase-type plasminogen activator (uPA). 1 The two polypeptide chains of plasmin are held together by disulfide bridges, and each polypeptide chain represents a distinct functional domain of the molecule. The larger polypeptide chain or A-chain (Lys 78 -Arg 561 ) contains five kringle domains, and the smaller polypeptide chain or B-chain (Val 562 -Asn 791 ) contains the serine protease domain. The kringle domains contain regions that bind to lysine residues of target proteins such as substrates, inhibitors, and cell-surface receptors. For example, the C-terminal lysine residues of the p11 subunit of annexin II tetramer mediate the binding of plasminogen to annexin II tetramer (2) .
Several biologically active, kringle-containing fragments of plasmin(ogen) have been shown to occur physiologically. It has been suggested that either tumor cells or the tumor-infiltrating cells such as macrophages express proteinases that are capable of cleaving plasminogen into fragments that consist of various truncations of the kringle-containing A-chain. Typically, these kringle-containing truncations consist of the first three (K1-3) or four (K1-4) kringle-containing domains (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Recently, it has been reported that in addition to their production by cancer cells or cancer-associated cells, plasminogen fragments similar to the angiostatins can be produced in non-neoplastic conditions such as a consequence of the inflammatory response (7, 17) . Furthermore, angiostatin and other A-chain fragments have also been detected in the tears collected after overnight eye closure suggesting that these fragments may also be produced under normal conditions (18) .
The biological activity of the K1-3 and K1-4 fragments are very similar. Since these A-chain fragments can inhibit experimental primary tumor growth as well as angiogenesis-dependent growth of metastases in mice, they have been referred to as angiostatins (13) (14) (15) . The mechanism of the anti-angiogenic effect of the angiostatins has been suggested to be due to endothelial cell apoptosis (16) .
Mechanistically, it is unclear how tumor cells or tumorassociated cells produce the A-chain fragments. One postulated mechanism involves the direct cleavage of plasminogen by extracellular proteinases. Dong et al. (6) postulated that the release of granulocyte-macrophage colony-stimulating factor by certain tumor cells may cause macrophages to release MMP-12, resulting in the cleavage of plasminogen to A-chain fragments. Alternatively, plasmin bound to the surface of macrophages may undergo autodigestion resulting in the generation of A-chain fragments (7) . It has also been postulated that prostrate carcinoma cells produce a K1-4 fragment by a twostep process involving the uPA-dependent conversion of plasminogen to plasmin followed by the reduction of plasmin disulfide bonds by free sulfhydryl donors and plasmin autodigestion (3, 19) . These authors also reported the absolute requirement of free sulfhydryl donors such as N-acetyl-L-cysteine for the generation of the K1-4 fragment by plasmin autodigestion in vitro. Alternatively, it has also been reported that HT1080 cells or Chinese hamster ovary cells may release a plasmin reductase and a novel serine proteinase that are responsible for conversion of plasmin to a A-chain fragments consisting of K1-4 and part of K5 (4, 5) . Therefore, the central dogma has been that A-chain fragment production from plasmin(ogen) is absolutely dependent on the presence of sulfhydryl donors and/or a plasmin reductase.
We sought to provide an independent analysis of the mechanism of A-chain fragment formation. Contrary to other reports, we have established that plasmin autodigestion can generate an A-chain fragment with angiostatin-like properties in the absence of free sulfhydryl donors or plasmin reductase. The major A-chain fragment produced by plasmin autodigestion is a novel fragment of 61 kDa that consists primarily of the amino acid sequence Lys 78 -Lys 468 and is composed of kringle domains 1-4 and part of kringle 5. We have also shown that a similar A-chain fragment is present in human serum and in serum from normal and tumor-bearing mice. Furthermore, nontransformed cells such as bovine capillary endothelial cells also produce a similar molecule. Our results provide the first evidence that anti-angiogenic plasminogen fragments are produced in a nonpathological setting simply as a consequence of plasmin turnover. Our data also suggest that plasmin autodigestion not only serves to regulate the concentration of plasma membrane-associated plasmin but also to regulate the production of anti-angiogenic plasmin fragments.
EXPERIMENTAL PROCEDURES
Materials- [Glu] plasminogen was purified from outdated pooled human plasma by affinity chromatography (20) . Both isoforms of [Glu-]plasminogen were used in the experiments described herein. [Lys 78 ]Plasminogen and two-chain urokinase-type plasminogen activator (uPA) were generous gifts from Dr. H. Stack (Abbott). Antibodies were purchased from the following sources: monoclonal anti-human plasminogen kringle 1-3 antibody from Enzyme Research Laboratories Inc; monoclonal anti-human angiostatin antibody (GF-47) from Oncogene Research Products; rabbit anti-mouse angiostatin antibody from Peptides International; anti-mouse horseradish peroxidase-conjugated secondary antibody from Santa Cruz Biotechnology. Purified commercial human angiostatin was purchased from Calbiochem. Cell lines were obtained from the following sources: HT1080 fibrosarcoma cells, Lewis lung carcinoma cells, and HeLa cells from American Type Culture Collection (ATCC); bovine capillary endothelial cells from Clonetics; human umbilical vein endothelial cells were a generous gift from Dr. Kamela Patel (University of Calgary). DMEM was obtained from JRH Biosciences and Life Technologies, Inc. Acetonitrile, ethyl acetate, and heptane were purchased from Burdick and Jackson. Diphenyl chlorophosphate, potassium thiocyanate, pyridine, pentanesulfonic acid, phosphoric acid, and all other organic solvents were purchased from Aldrich. Reagent 4R and the amino acid thiohydantoin standard mixture for the HP G1000A were purchased from Hewlett-Packard.
Angiostatin Generation- [Glu] plasminogen (40 M) was incubated in the presence or absence of 1 mM N-acetyl-L-cysteine (NAC) and buffer containing 50 mM Tris-HCl (pH 9.0), 20 mM L-lysine, 100 mM NaCl, 1 mM EDTA, and 0.17 M two-chain uPA. The reaction mixture was incubated overnight at 37°C, diluted 4-fold with 20 mM Hepes (pH 7.4) and 140 mM NaCl, adjusted to 1 mM DIFP, and applied to a L-lysineSepharose column (previously equilibrated with 20 mM Hepes (pH 7.4) and 140 mM NaCl). After a 5-column volume wash with the equilibration buffer, the column was subjected to a linear gradient of 0 -125 mM ⑀-ACA, and a single protein peak was eluted, pooled, and concentrated by ultrafiltration. Application of this protein peak to Sephacryl S-100 column (previously equilibrated with 20 mM Hepes (pH 7.4) and 140 mM NaCl) resulted in the elution of a single protein peak that was pooled and frozen at Ϫ80°C in small aliquots. Reduced SDS-PAGE established that this protein peak was composed of a doublet consisting of a major and minor Coomassie Blue-stained protein bands of 61 and 64 kDa, respectively (Fig. 1A) . Therefore, these A-chain fragments were named A 61 . The concentration of A 61 was determined using an ⑀ 1%,280 nm 13 Immediately before use in the endothelial cell proliferation assay, aliquots of A 61 were applied to a Detoxi-Gel column (Pierce), and endotoxin was removed according to the manufacturer's instructions. Endotoxin contamination of the purified angiostatin was analyzed by Pyrotell Limulus amebocyte lysate assay (Associates of Cape Cod Inc, Falmouth, MA) and was less than 45 pg of endotoxin/ml (0.4 enzyme units/ml).
Cell-mediated Generation of Angiostatin-HT1080 cells were maintained in DMEM (Life Technologies, Inc.) supplemented with 10% heatinactivated fetal bovine serum, 2 mM L-glutamine, 10 units/ml penicillin G, and 10 M streptomycin sulfate. Approximately 1 ϫ 10 5 cells in 1 ml were added to each well of 24-well tissue culture plates and incubated at 37°C for 24 h. The cell monolayers were then washed three times with PBS (PBS, phosphate-buffered saline (137 mM NaCl, 8 mM Na 2 HPO 4 , 1.4 mM KH 2 PO4, 2.7 mM KCl, pH 8.0)), and 0.5 to 8 M [Glu]plasminogen in DMEM was added to each well. After overnight incubation, the media were removed and diluted with SDS-PAGE sample buffer with or without ␤-mercaptoethanol and subjected to SDS-PAGE and Western blotting with the monoclonal anti-human plasminogen kringle 1-3 antibody as indicated below.
To isolate sufficient cell generated A 61 , HT1080 or BCE cells, cultured in T75 tissue culture flasks, were incubated overnight with DMEM containing 2.7 M human [Glu] plasminogen. The culture supernatants (about 100 ml) were centrifuged at 2000 ϫ g at 4°C for 30 min to remove cell debris. The supernatants were then applied to a L-lysine-Sepharose column previously equilibrated with 20 mM Hepes (pH 7.4) and 140 mM NaCl. The column was subsequently washed with 5 column volumes of the equilibration buffer, and the bound proteins were eluted with a 0 -0.125 M ⑀-ACA gradient. The fractions were analyzed by SDS-PAGE, and the peak fractions containing A 61 were pooled and concentrated. The proteins were desalted using a Sephadex PD-10 column (Amersham Pharmacia Biotech) into endotoxin-free PBS (Life Technologies, Inc.), filtered, and frozen in small aliquots at Ϫ80°C.
Endothelial Cell Proliferation Assay-Bovine capillary endothelial cells were maintained in DMEM (JRH Biosciences) supplemented with 10% calf serum, 2 mM L-glutamine, 10 units/ml penicillin G, 10 M streptomycin sulfate, and 3 ng/ml bFGF (Calbiochem). BCE cells between passages 3 and 5 were plated into 24-well tissue culture plates (3,000 cells/well) and incubated at 37°C for 24 h. The medium was replaced with fresh DMEM containing 5% calf serum in the presence or absence of A 61 . After a 30-min incubation, bFGF was added to a final concentration of 1 ng/ml, and cells were further incubated for 72 h. The cells were trypsinized, resuspended in Isoton II (Beckman), and counted with a Coulter counter.
Analysis of Angiostatin in Serum-200 l of mouse or human serum was incubated at room temperature for 30 min with 50 l of a 1:1 suspension of L-lysine-Sepharose matrix (previously equilibrated with 20 mM Hepes (pH 7.4), 140 mM NaCl). The matrix was subsequently washed extensively with 5 volumes of the same buffer. The bound proteins were eluted by boiling the resin with SDS-PAGE sample buffer, and 20 l of each sample was subjected to nonreduced SDS-PAGE and Western blotting (below).
Murine Tumor Model-Lewis lung carcinoma cells were grown, harvested at log phase, and resuspended in PBS. Approximately 10 6 cells were injected subcutaneously in the middle dorsum of 6 -8-week-old C57BL/6 male mice. When tumors reached 1500 mm 3 in size (ϳ14 days after implantation), the mice were randomly separated into two groups. The first group underwent surgical removal of the tumor, and the second group was subjected to a sham surgical procedure in which tumors were manipulated but were left intact. Animals from the tumorresected group were randomly placed into test and control groups. The test group of mice received daily intraperitoneal injections of A 61 in PBS (dose ϭ 2.5 mg/kg/day), whereas the control group received PBS alone. Every 3rd day after tumor resection, mice were sacrificed, and the lungs were weighed.
N-and C-terminal Sequencing of Angiostatin-N-terminal sequence analysis was performed by the University of Calgary Sequence Analysis Facility and Alberta Peptide Institute (Edmonton, Canada). C-terminal sequence analysis was performed by the Beckman Research Institute of the City of Hope (Duarte, CA). A 61 was sequenced using a HewlettPackard HP G1000A C-terminal protein sequencer and an Applied Biosystems 477C Procise C C-terminal sequencer. Consistent results were obtained with both sequencers. The Hewlett-Packard HP G1000A, C-terminal protein sequencer utilized chemistry version 2.0 using diphenylphosphorylisothiocyanate as the activating agent (21) and a modified cleavage system using lithium ethiolate as the cleavage agent (48) . Applied Biosystems 477C Procise C C-terminal sequencer was running standard chemistry as described (22) .
Electrophoresis and Western Blotting-Samples were diluted with SDS-PAGE sample buffer in the presence (reduced SDS-PAGE) or [Glu]plasminogen (Pg) (8.7 M) was incubated at 37°C in a buffer containing 50 mM Tris (pH 9.0), 100 mM NaCl, 1 mM EDTA, and 20 mM L-lysine. The reaction was initiated by addition of 39 nM uPA, and aliquots of the reaction were removed at the indicated times, subjected to reduced (A) and nonreduced-SDS-PAGE (B), and stained with Coomassie Blue. Pm H , plasmin heavy chain; Pm L , plasmin light chain. equilibrated with 20 mM Hepes (pH 7.4) and 140 mM NaCl). After a 5-column volume wash with the equilibration buffer, the column was subjected to a linear gradient of 0 -125 mM ⑀-ACA gradient. Fractions containing 61-and 64-kDa plasminogen fragments were pooled (lane 3), concentrated by ultrafiltration, and applied to a Sephacryl gel permeation (Gel Perm) chromatography column previously equilibrated with 20 mM Hepes (pH 7.4) and 140 mM NaCl. The protein peak was then pooled (lane 4). Aliquots of pooled fractions were analyzed by reduced (A) and nonreduced SDS-PAGE (B) and stained with Coomassie Blue. Alternatively, aliquots were analyzed by nonreduced SDS-PAGE, transferred to nitrocellulose, and Western blotted using the monoclonal anti-human plasminogen kringle 1-3 antibody (C).
absence (nonreduced SDS-PAGE) of ␤-mercaptoethanol and subjected to SDS-PAGE (23) . Proteins were transferred to 0.45-m pore size nitrocellulose membrane using a Bio-Rad transblot apparatus at 4°C for 1 h for mini-gels or overnight for larger gels. The membrane was blocked in TPBS (where TPBS is phosphate-buffered saline containing 137 mM NaCl, 8 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 , 2.7 mM KCl (pH 8.0), and 0.1% Tween 20) containing 5% skim milk at room temperature for 1 h and then incubated with primary antibody in TPBS containing 1% skim milk at 4°C overnight. The following dilutions of primary antibody were used: 1:5000 dilution of 1 mg/ml monoclonal anti-human plasminogen kringle 1-3 antibody; 1:500 dilution of 0.1 mg/ml monoclonal anti-human angiostatin antibody (GF-47); 1:500 dilution of polyclonal anti-mouse angiostatin antibody. The blot was then washed with TPBS at least 6 times (10 min each) at room temperature and then incubated in 1:1000 dilution of anti-mouse or anti-rabbit horseradish peroxidase-conjugated secondary antibody in TPBS containing 1% skim milk at 37°C for 1 h. The membrane was extensively washed with TPBS at least six times (10 min each), developed with the Supersignal reagent (Pierce), and visualized by chemiluminescence.
Circular Dichroism-Circular dichroism (CD) measurements were performed with a Jasco J-810 spectropolarimeter. The spectropolarimeter was calibrated with an aqueous solution of recrystallized ammonium d-10-camphorsulfonate. A 61 (0.4 -0.6 mg/ml) was incubated in 10 mM Tris-HCl (pH 7.5) and 150 mM NaCl in the presence or absence of ligand for 20 min at room temperature. Samples (0.1 ml) were scanned in a quartz cuvette (0.5-mm path length) from 178 to 260 nm at a rate of 20 nm/min, using a bandwidth of 1 nm and a response time of 4 s. CD spectra of proteins were obtained by averaging three wavelength scans and were corrected by subtracting buffer scans or, where appropriate, scans of ligand in buffer. Results are expressed as ⌬⑀(M Ϫ1 ⅐cm
Ϫ1
). The A 61 secondary structure content was assessed with the program CDsstr version 1.8 (24) .
Intrinsic Fluorescence Measurements-Excitation and emission spectra were collected with a PerkinElmer Life Sciences LS 50B fluorescence spectrometer equipped with a constant temperature cell holder. The excitation and emission slit widths were set to 5 and 10 nm, respectively. The spectra were collected at 25°C with A 61 (3.7 M) in a buffer consisting of 20 mM Hepes (pH 7.4) and 140 mM NaCl and in the presence or absence of ligand. The data were corrected for the slight dilution consequent to ligand additions.
Measurement of Molecular Mass by Mass Spectrometry-Mass spectrometry was performed by the Beckman Research Institute of the City of Hope. Matrix-assisted laser desorption ionization (MALDI) mass spectra were obtained using a Voyager DE-STR (PE Biosystems) MALDI time-of-flight mass spectrometer. The analyte solutions were individually loaded onto pre-equilibrated ZipTips (Millipore Corp.) in four 4-l increments, for de-salting and pre-concentration. The analytes were each eluted from their Tip with 2 l of recrystallized Sinapinic (3,5-dimethoxy-4-hydroxycinnamic acid) matrix solution, 1 l at a time, onto a 100-well stainless steel sample slide. After introduction of the slide into the mass spectrometer, a linear MALDI method was employed to obtain sample spectra. The method employed a 20-kV accelerating voltage, a nitrogen laser (337 nm, UV wavelength), and a 350-ns extraction delay time. Each data set was noise-filtered, smoothed twice, entroided, and de-isotoped. This processing removes the confusion of isoform mass overlap by removing the isotope contributions from the centroided-isoform spectrum.
RESULTS

Identification of the Plasmin(ogen) Fragments Produced by
Plasmin Autodigestion in Vitro-Gately et al. (19) observed that a K1-4-containing plasminogen cleavage product of 50 kDa (nonreduced SDS-PAGE) was generated in a cell-free system consisting of plasminogen, uPA, and N-acetyl-L-cysteine. Interestingly, it was also reported that the formation of the K1-4 plasminogen A-chain fragment was absolutely dependent on the presence of a sulfhydryl donor such as N-acetyl-Lcysteine. However, in a previous report we observed that plasmin autodigestion resulted in the generation of a similar A-chain fragment in the absence of sulfhydryl donors (25) . To 
TABLE II Comparison of various A-chain fragments
The abbreviations used are: K, kringle; r, amino acid residues; MME, macrophage metalloelastase. Numbering is based on the sequence of human plasminogen (791 residues) excluding the 19 amino acid signal peptide that ends at Met 19 and beginning at Glu 1 (47) . The angiostatin activity of the A-chain fragments, the IC 50 , was determined as the concentration of A-chain fragment required to half-maximally inhibit the proliferation of bovine capillary endothelial cells. To allow a direct comparison of the angiostatin activity, results were pooled from several reports (14) . re-examine the issue of the requirement of sulfhydryl donors for the generation of A-chain fragments, we incubated human plasminogen with uPA overnight without any sulfhydryl donor. The reaction products were then purified by L-lysine-Sepharose affinity and gel permeation chromatography. We found that the overnight incubation of plasminogen with uPA resulted in the generation of a doublet of apparent mass of 61 and 64 kDa, respectively, on a Coomassie-stained, denaturing, reduced SDS-PAGE (Fig. 1A) . The two fragments produced a diffuse band of an apparent mass of 50 kDa on Coomassie-stained, denaturing, nonreduced SDS-PAGE (Fig. 1B) . These plasminogen fragments reacted with a monoclonal antibody against the K1-3 fragment of plasminogen, confirming that the plasminogen fragments isolated by our procedure were A-chain fragments (Fig. 1C) . Since the major A-chain fragment produced in our cell-free system was 61 kDa on reduced SDS-PAGE, we have named this plasminogen fragment A 61 . Typically, we recovered 51 mg of A 61 from 100 mg of plasminogen. The A 61 could have been produced in our cell-free system as a result of the cleavage of plasminogen to plasmin by the uPA followed by the autodigestion of this plasmin. Alternatively, the direct cleavage of plasminogen by plasmin could have been responsible for the generation of A 61 .
To examine further the mechanism of A 61 production, we examined the time course of generation of A 61 from plasminogen and uPA. As shown in Fig. 2A , 5 min after initiation of the reaction, the plasminogen was completely converted to plasmin, and the plasmin heavy and light chains were visualized by reduced SDS-PAGE. However, at this point in the reaction, A 61 was not present. After the reaction progressed for about 1 h, degradation of the plasmin heavy and light chains was apparent. At 2-4 h the plasmin light chain had disappeared, whereas little change in the plasmin heavy chain was apparent. However, analysis of the 2-4-h reaction by nonreduced SDS-PAGE clearly showed that during this period A 61 was generated (Fig.  2B) . We also observed that a recombinant human plasminogen (S741C) that is catalytically inactive when converted to plasmin was not converted to A 61 (data not shown). These results therefore suggest that plasminogen is cleaved by uPA to form plasmin which then undergoes autodigestion resulting in the formation of A 61 .
Characterization of A 61 -The large scale purification of A 61 from plasminogen allowed a detailed characterization of the structure of the molecule. The N- . The average molecular mass measured from this amino acid sequence is 44.1 kDa. Mass spectrometry of A 61 revealed a broad cluster of features of about 1-kDa width. The dominant species in the cluster smoothed into a M r of 46,616 when the cluster was centroided and de-isotoped. The 44.1-kDa fragment derived from the analysis of the primary structure is significantly smaller than the average apparent mass of 46.6 kDa measured by mass spectrometry. This difference is probably due to the glycosylation of the molecule (26, 27) .
A comparison of the amino acid sequence of A 61 with other A-chain fragments is presented in Table II . These data establish that A 61 is a novel A-chain fragment. The sequence of the molecule suggests that A 61 is similar to other A-chain fragments such as K1-4 angiostatin. However, unlike the majority of angiostatins, A 61 consists of the first four kringles of plasminogen plus the K4-K5 linker region and seven residues of the fifth kringle.
We used circular dichroism to examine the secondary structure of A 61 (Fig. 3A) . The far-UV circular dichroism spectrum of A 61 exhibited a strong negative band at 202 nm and a weak positive band at about 227 nm. This spectrum is similar to that reported for other kringle containing A-chain fragments such as K4 (28 -30) . Analysis of the secondary structure content from CD spectra yields about 21% ␤-strand, 14% ␤-turn, 18% 3 1 -helix, 8% 3 10 -helix, and 40% unordered. Similar to other kringle-containing structures, A 61 does not contain any ␣-helix structure. These results established that the A 61 generated in the cell-free system in the absence of a sulfhydryl donor did not result in the denaturation of the molecule.
The kringles of plasminogen play a critical role in substrate recognition and in determining the conformation of plasminogen. The binding of lysine-type zwitterions such as ⑀-ACA to the kringles of plasminogen results in an increase of about 7% in the intrinsic protein fluorescence (31) . N-acetyl-L-lysine (which mimics the structure of a C-terminal lysine) caused a significant increase in the intrinsic fluorescence emission spectra. AMCHA caused the largest increase (27%) in fluorescence intensity of the emission spectra. However, N-acetyl-L-lysine methyl ester, a lysine analogue that mimics the structure of an internal lysine residue, did not cause a significant change in the fluorescence emission spectra. These data are summarized in Table III . These results suggest that the kringles of A 61 are functionally active and can bind to free lysine residues or C-terminal lysine residues but not to internal lysine residues.
Biological Activity of A 61 -To investigate whether A 61 had angiostatin-like activity, we examined the ability of A 61 to inhibit endothelial cell proliferation. Purified A 61 was incubated with BCE cells that were stimulated with 1 ng/ml FGF. A 61 inhibited BCE cell growth in a dose-dependent manner (Fig. 4A) We also examined the anti-angiogenic activity of A 61 in vivo. C57 BL/6 mice were inoculated with Lewis Lung carcinoma cells, and after 14 days the tumor was resected. One group of mice received daily intraperitoneal injections of 2.5 mg of A 61 / kg, whereas the control group received PBS (Fig. 4B) . The lung weight of the PBS-treated, tumor-resected mice increased over time. Eighteen days after the tumor resection, lung weight, which correlated with total tumor burden, reached 770 Ϯ 42 mg (n ϭ 4). In contrast, the average lung weight of the mice that received daily doses of A 61 increased only to 250 Ϯ 14 mg (n ϭ 4). The average weights of lungs of normal and 18-day tumorbearing mice were 191 Ϯ 25 (n ϭ 4) and 199 Ϯ 20 mg (n ϭ 4), respectively. The increase in the weight of the lungs in the tumor-resected mice corresponded with an increase in the metastatic foci that were observable (data not shown). These results establish that A 61 is a potent anti-angiogenic protein.
Identification of Cell-generated Plasminogen FragmentsThe ability of many cells to bind plasminogen at the cell surface has been well established. Whereas plasminogen can be converted to plasmin at the cell surface by the action of plasminogen activators such as uPA, it has been recently shown that other plasminogen fragments are also produced at the cell surface (3, 32, 33) . To compare the plasminogen fragments produced on the cell surface with A 61 , HT1080 fibrosarcoma cells were incubated with plasminogen, and the cell-produced plasminogen fragments were analyzed by reduced (Fig. 5A) or nonreduced (Fig. 5B ) SDS-PAGE and Western blotting. When [Glu]plasminogen was incubated overnight in DMEM in the absence of cells, an A 61 -like plasminogen fragment was faintly detected with the monoclonal anti-human plasminogen kringle 1-3 antibody. However, in the presence of HT1080 cells, a plasminogen fragment of comparable molecular mass to A 61 was easily detected. The concentration of this plasminogen fragment increased with increasing plasminogen concentrations.
Several other cell lines were compared with HT1080 cells for their ability to produce plasminogen fragments. Although plasminogen fragments were barely detected in the media obtained from HeLa and HUVEC, we found that the media from BCE cells contained A 61 -like plasminogen fragment (Fig. 5C ). This result demonstrated that normal cells and not just cancer cells could produce A 61 -like plasminogen fragments.
Although our data established that normal and cancerous cells produce an A 61 -like plasminogen fragment, it does not establish if these fragments are biologically active. Therefore, we incubated HT1080 and BCE cells with plasminogen and purified the A 61 -like plasminogen fragment from the conditioned media by affinity chromatography. As shown in Fig. 5D , the A 61 -like plasminogen fragment released into the media by HT1080 or BCE cells inhibited the proliferation of bovine cap- illary endothelial cells with similar potency and was therefore biologically active. The concentration of A 61 -like plasminogen fragment produced by HT1080 and BCE cells necessary for half-maximal inhibition was about 45 nM. The A 61 -like plasminogen fragments that were isolated from the conditioned media of the HT1080 or BCE cells were also subjected to N-terminal analysis. These data showed that the N-terminal amino acid sequence of the A 61 -like plasminogen fragment obtained from the media of the HT1080 or BCE cells were identical (Table IV) . Furthermore, the N-terminal sequence of the cell-produced protein was identical to the Nterminal sequence of the A 61 protein produced by our cell-free system.
Identification of Plasminogen Fragments Present in Sera-It was originally proposed that an A-chain plasminogen fragment of 38 -43 kDa on reduced SDS-PAGE was present in the urine and serum of mice bearing Lewis lung carcinoma tumors. This A-chain fragment was named angiostatin and was shown to be present in the serum of tumor-bearing mice but not in the serum of normal mice or tumor-resected mice (13) . However, as shown in Fig. 6A , the serum from normal, tumor-bearing, and tumor-resected mice all had detectable levels of an A 61 -like plasminogen fragment. This mouse plasminogen fragment ran with a mass of about 50 kDa on nonreduced SDS-PAGE and was also detectable with a anti-human K1-3 monoclonal antibody (Fig. 6C, aЈ) . We also examined the serum of mice for several days after tumor resection. We did not observe an appreciable change in the concentration of A 61 -like plasminogen fragment from 3 to 15 days after tumor resection (Fig. 6, B  and C, bЈ) .
The results obtained with mouse serum suggested that A 61 -like plasminogen fragments were present in the serum of normal and tumor-bearing animals. We therefore examined the serum of healthy human volunteers and found the presence of an A 61 -like plasminogen fragment in all of the subjects examined (Fig. 7A) . The human plasminogen fragment corresponded with the upper band of our A 61 . We then examined the serum of patients diagnosed with several forms of cancer. As shown in Fig. 7B , all patients tested demonstrated the presence of an A 61 -like plasminogen fragment in their serum.
DISCUSSION
Our initial studies of the mechanism of plasmin autodigestion had shown that a major product of the plasmin autoproteolytic reaction was an A-chain plasmin fragment of approximately 61 kDa (25) . This report contrasted with an earlier report that concluded that the generation of an A-chain fragment with angiostatin-like activity in a cell-free system required plasminogen and uPA and was absolutely dependent on the presence of a sulfhydryl donor (19) . Here, we sought to provide an independent analysis of the mechanism of A-chain formation. In this communication we report that two A-chain fragments were generated from plasminogen and uPA in the absence of a sulfhydryl donor. Since the major protein band on SDS-PAGE was 61 kDa, we named the A-chain fragment A 61 . Since the uPA-dependent conversion of plasminogen to plasmin precedes the formation of A 61 , we have concluded that plasmin autodigestion is responsible for the formation of A 61 . The availability of large quantities of A 61 has allowed characterization of the structure, function, and physiological relevance of this Achain fragment.
N-and C-terminal sequencing has allowed the precise elucidation of the primary structure of A 61 as comprising the amino acid sequence Lys 78 -Lys 468 . Other A-chain fragments have been reported, but the absence of C-terminal sequencing has made the exact identification of these fragments difficult. Plasminogen is cleaved by a variety of proteinases including metalloelastase, matrix metalloproteinases, and serine proteinases to generate K1-3, K1-4, and K1-4.5 fragments (Table II) . Typically these A-chain fragments terminate at amino acid residues in the linker regions between the K3 and K4 (Cterminal Val 338/354 residues for K1-3), the linker regions between K4 and K5 (C-terminal Ala 440 or Pro 446/447 for K1-4), or within residues of K5 (C-terminal Arg 530 for K1-4.5). Therefore, A 61 is a novel A-chain fragment that belongs to the K1-4.5 class of A-chain fragments except that it contains only 7 residues of K5.
Comparison of the 46.6-kDa fragment of A 61 derived from mass spectrometric analysis with the 44.5-kDa fragment derived from the amino acid sequence of the protein suggests that like the parent molecule, plasminogen, A 61 is glycosylated. Plasminogen contains N-linked carbohydrate residues on K3 and two O-linked carbohydrate on Ser 249 and Thr 346 of the K2-K3 linker and K3-K4 linker, respectively. The role of these glycosylations is unclear, but studies of A-chain fragment glycoforms have suggested that the extent of glycosylation may affect the biological activity or half-life of the protein in circulation (34) .
The availability of milligram quantities of A 61 has allowed detailed analysis of the secondary structure of the molecule. The absence of ␣-helical structure in A 61 was indicated from analysis of the far-UV CD spectrum using CDsstr, a recently released computer program (24) . Overall, the secondary structure of A 61 is comparable to other kringle-containing proteins. Recently, it was demonstrated that kringle-containing proteins contain significant 3 1 -helix. This structure was not reported in earlier x-ray structures because of the difficulty in visualization. However, the far-UV CD spectrum is uniquely sensitive to 3 1 -helix. The presence of 3 1 -helix in A 61 is consistent with the 3 1 -helix structures recently reported for other kringle-containing structures such as plasminogen (35) . Since the intrinsic fluorescence emission spectrum of A 61 increased in the presence of lysine or lysine analogues, we have concluded that the kringles of A 61 are functionally active.
A 61 inhibits the proliferation of BCE cells and blocks the growth of Lewis lung carcinoma metastatic foci in C57BL/6 mice. The IC 50 for inhibition of endothelial proliferation by A 61 , prepared in the presence or absence of NAC, was identical. However, our IC 50 of 35 nM is significantly lower than the IC 50 of 300 nM reported by Soff and co-workers (19) . It is unclear why this difference in potency is observed. Interestingly, the dosage of A 61 used in our experiments to inhibit the growth of Lewis lung metastatic foci in mice, 2.5 mg/kg/day, was also lower than the 15 mg/kg/day used by Soff and co-workers. A 61 is therefore as biologically active as the A-chain fragment made in the presence of sulfhydryl donors. Since A 61 blocks the growth of metastatic foci, it is by definition an angiostatin.
The concept that plasmin is capable of autodigestion in the absence of sulfhydryl donors is not novel. Other laboratories have shown that plasmin autodigestion involves a bimolecular reaction in which both heavy and light chains are proteolyzed (36 -42) . Two autodigestive processes involving human plasmin have been reported by Wu and co-workers (42) . In a slightly acidic solution the light chain was found to be cleaved faster than the heavy chain of plasmin. The cleavage of the light chain correlated with loss of plasmin activity. Both the heavy chain and the light chain were cleaved at pH levels between 6.5 and 11.0. On the other hand, alkaline pH favored the cleavage of the heavy chain. A cleaved heavy chain of molecular weight 50,000 (reduced SDS-PAGE) (36) or 58,000 was observed (42) . The C terminus of the M r 58,000 fragment was shown to be Arg 530 (41) . Based on these data it has been theorized that because of their proximity in the plasminogen structure, the disulfide bonds between We also compared A 61 with A-chain fragments that were produced by cultured cells or that were present in mouse or human serum. First, we found that cultured cells produced a plasminogen fragment of similar M r to that of A 61 which suggested that the predominant cell-produced A-chain fragment was composed of at least four intact kringles. Second, the observation that BCE cells produced an A 61 -like protein suggested that the formation of A-chain fragments was not restricted to cancer cells. Furthermore, the N-terminal sequencing of the A 61 -like plasminogen fragment produced by the HT1080 or BCE cells established that the N terminus of the cell produced A 61 was identical to the A 61 produced in our cell-free system. Our observation that the A 61 -like protein produced by HT1080 or BCE cells possessed potent anti-angiogenic activity further supports our notion that normal unstimulated cells can produce anti-angiogenic plasminogen fragments. Third, we also observed the presence of an A-chain fragment similar to A 61 in mouse and human serum. The plasminogen fragment present in mouse serum was of similar size to the lower molecular weight band of A 61 , whereas the plasminogen fragment present in human serum was of similar size to the higher molecular weight form of A 61 . These observations are consistent with the size of the A-chain fragments produced by cultured cells and suggest that the physiological A-chain fragment is about 61 kDa. However, it is not clear if the A 61 -like plasminogen fragment detected in the sera of normal, tumor-bearing, or tumor-resected mice are biologically active. Further experiments will be necessary to establish the amino acid sequence 61 Human A 61 was generated from human plasminogen and uPA in the cell-free system as described under "Experimental Procedures." Conditioned media from human HT1080 fibrosarcoma and bovine capillary endothelial cells were subjected to affinity chromatography with L-lysine-Sepharose, and the bound proteins were subjected to SDS-PAGE. The protein band corresponding to A 61 was sliced from the gel and subjected to N-terminal sequencing. and carbohydrate sequence of the physiological A-chain fragment. Circulating plasminogen consists of two glycoforms, and each glycoform is heterogeneous with respect to the size of the carbohydrate side chains resulting in at least six additional species for each glycoform. It will therefore be interesting to see if the circulating A-chain fragment is also heterogeneous. Fourth, we found an A 61 -like protein in the serum of normal mice and humans. This result suggests that A-chain fragments are not exclusively produced in a pathophysiological setting.
In conclusion, it has been suggested that angiostatin-like A-chain fragments are produced by the primary tumor as a means of inhibiting the growth of metastatic foci. Our experiments, however, have shown that this conceptually satisfying hypothesis does not accurately reflect the situation in vivo. Rather, we propose that the A 61 -like A-chain fragments can be produced merely as a function of plasmin autodigestion. Although our data establish that normal, tumor-bearing, and tumor-resected mice or normal or tumor-bearing humans produce the A 61 -like A-chain fragment at comparable levels, we cannot at this time establish if the A 61 -like A-chain fragment detected in the sera of mice and humans is biologically active. Since these proteins were purified by affinity chromatography with L-lysine-Sepharose, we can conclude that the kringles of the proteins were not functionally compromised.
FIG. 6.
Comparison of A 61 with plasminogen fragments present in mouse sera. Mice sera were incubated with 50 l of L-lysineSepharose (equilibrated in 20 mM Hepes, (pH 7.4), 140 mM NaCl) for 30 min at room temperature. The matrix was washed with 5 volumes of equilibration buffer, boiled with SDS-PAGE sample buffer, and subjected to nonreduced SDS-PAGE. Western blotting was performed with rabbit anti-mouse angiostatin antibody (A) or monoclonal anti-human plasminogen kringle 1-3 antibody (B). The lanes in A are as follows:, control mouse serum (1 and 2) ; mouse serum from two individual mice with 14-day old tumor (3 and 4) ; mouse serum from two individual mice 14 days after tumor resection (5 and 6). The lanes in B are as follows: A 61 standard (1); mouse with 14-day old tumor (2); 3 days after tumor resection (3); 6 days after tumor resection (4); 9 days after tumor resection (5); 12 days after tumor resection (6); 15 days after tumor resection (7) . Alternatively, the Western blot presented in A and B were probed with human monoclonal anti-human plasminogen kringle 1-3 antibody (C, aЈ) or rabbit anti-mouse angiostatin antibody (C, bЈ), respectively. The results in A were consistent with our test groups consisting of 21 normal mice, 9 tumor-bearing mice, and 29 tumor-resected mice. 5) ; testicular cancer (lanes 6 -8); head and neck cancer (lanes 9 and 10).
